Brimonidine

Bibliography

• THYLEFORS B, NEGREL AD: The global impact of glau- coma. Bull. World Health Org. (1994) 72(3):323–326.
   PubMed Web of Science ®Google Scholar
• QUIGLEY HA: Number of people with glaucoma world- wide. Br. J. Ophthalmol. (1996) 80:389–393.
   PubMed Web of Science ®Google Scholar
• JAVITT JC: Cost/utility of glaucoma: impact on managed care. Under Pressure: Glaucoma 1994. CD-ROM. American Academy of Ophthalmology and Mosby-Year Book (1995).
   Google Scholar
• AMERICAN ACADEMY OF OPHTHALMOLOGY: Basic and Clinical Science Course: Glaucoma. American Academy of Ophthalmology, San Francisco (1996). Section 10.
   Google Scholar
• AMERICAN ACADEMY OF OPHTHALMOLOGY: Primary Open-Angle Glaucoma, Preferred Practice Pattern. American Academy of Ophthalmology, San Francisco (1992).
   Google Scholar
• TIELSCH JM, SOMMER A, KATZ J et al.: Racial variations in the prevalence of primary open angle glaucoma. The Baltimore Eye Survey. JANIA (1991) 266:369–374.
   Google Scholar
• GIESER SC, JUZYCH M, ROBIN AL et al: Clinical pharma-cology of adrenergic drugs. In: The Glaucomas (2nd Edition). Ritch R, Shields MB, Krupin T (Eds.), Mosby, St. Louis (1996):1425–1448.
   Google Scholar
• BOGER WP, III: Short-term 'escape' and long-term 'drift'. The dissipation effects of the beta-adrenergic blocking agents. Sun'. Ophthalmol. (1983) 28:235–240.
   Google Scholar
• LIN LL, GALIN MA, OBSTBAUM SA et al.: Long-term timolol therapy. Sun'. Ophthalmol (1979) 23(6):377–380.
   PubMed Web of Science ®Google Scholar
• STEINERT RF, THOMAS JV, BOGER WP: Long-term drift and continued efficacy after multiyear timolol therapy. Arch. Ophthalmol. (1981) 99:100.
   PubMed Web of Science ®Google Scholar
• FRISHMAN WH, FUKSBRUMER MS, TANNENBAUM M: Topical ophthalmic I3-adrenergic blockade for the treat-ment of glaucoma and ocular hypertension. J. Clin. Pharmacol. (1994) 34:795–803.
   PubMed Web of Science ®Google Scholar
• SINGH K, ZIMMERMAN TJ: Update on the status of topical beta blockers in the treatment of glaucoma. Ophthalmol Clinics N Am. (1995) 8(2):295–302.
   Google Scholar
• SORENSEN SJ, ABEL SR: Comparison of the ocular beta-blo cke rs. Ann. Pharmacother. (1996) 30 (1) :43–54.
   PubMed Web of Science ®Google Scholar
• MCMAHON CE, SHAFFER RN, HOSKINS HD, Jr. et al.:Adverse effects experienced by patients taking timolol. Am. J. Ophthalmol (1979) 78:736.
   Google Scholar
• VAN BUSKIRK EM: Adverse reactions from timolol ad-ministration. Ophthalmology (1980) 87:447.
   PubMed Web of Science ®Google Scholar
• WEINREB RN, VAN BUSKIRK EM, CHERNIACK R et al.: Long-term betaxolol therapy in glaucoma patients with pulmonary disease. Am. J. Ophthalmol. (1988) 106:162–167.
   PubMed Web of Science ®Google Scholar
• BROOKS AMV, GILLIES WE: Ocular beta-blockers in glau-coma management. Drugs Aging (1992) 2:208–221.
   PubMed Web of Science ®Google Scholar
• HARRIS LS, GREENSTEIN SH, BLOOM AF: Respiratory difficulties with betaxolol [letter]. Am. J. Ophthalmol. (1986) 102:274.
   PubMed Web of Science ®Google Scholar
• ALLEN RC, HERTZMARK E, WALKER AM et al.: A double-masked comparison of betaxolol vs. timolol in the treatment of open-angle glaucoma. Am. J. Ophthalmol. (1986) 101:535–541.
   Google Scholar
• LIPPA EA: Carbonic anhydrase inhibitors. In: The Glau-comas (2nd Edition). Ritch R, Shields MB, Krupin T (Eds.), Mosby, St. Louis (1996):1463–1480.
   Google Scholar
• BRANDT JD: Carbonic anhydrase inhibitors. CIAO J. (1991) 17(2):136–138.
   Google Scholar
• HIGGINBOTHAM EJ: Dorzolamide: a brief overview. Chi-bret Int. J. Ophthalmol. (1994) 10(3):50–53.
   Google Scholar
• STRAHLMAN E, TIPPING R, VOGEL R et al.: A double-masked, randomized 1-year study comparing dorzo-lamide (Trusopt), timolol, and betaxolol. Arch. Ophthalmol. (1995) 113:1009–1016.
   PubMed Web of Science ®Google Scholar
• MAUS TL, LARSSON L-I, MCLAREN JW et al.: Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Arch. Ophthalmol (1997) 115:45–49.
   PubMed Web of Science ®Google Scholar
• NARDIN GF, ZIMMERMAN TJ: Ocular cholinergic agents. In: The Glaucomas (2nd Edition). Ritch R, Shields MB, Krupin T (Eds.), Mosby, St. Louis (1996):1399–1407.
   Google Scholar
• ALLEN RC: Medical management of glaucoma. In: Princi-ples and Practices of Ophthalmology Albert DM, Jakobiec FA (Eds.), (1993) :1569–1588.
   Google Scholar
• KEATES EH, BAARVELDT G, CHAPMAN BS et al.: Long-term efficacy and safety of dipivefrin in open-angle glaucoma and ocular hypertension. In: Acta XXV Con cil-iumOphthalmologicum. Blondi F et al. (Eds.), Kugler and Ghedini, Rome (1988) :1448–1452.
   Google Scholar
• NOVACK GD, ROBIN AL, DERICK RJ: New medical treat-ments for glaucoma. mt. Ophthalmol Clin. (1993) 33:183–202.
   PubMedGoogle Scholar
• HODAPP E, KOLKER A, KASS M et al: The effect of topical clonidine on intraocular pressure. Arch. Ophthalmol (1981) 99:1208–1211.
   PubMed Web of Science ®Google Scholar
• British National Formulary. British Medical Association and Royal Pharmaceutical Society of Great Britain (1996) 32:441.
   Google Scholar
• YeKSEL N, GÜLER C, CAGLAR Y et al.: Apraclonidine and clonidine: a comparison of efficacy and side-effects in normal and ocular hypertensive volunteers. mt. Ophthalmol. (1992) 16(4-5):337–342.
   Web of Science ®Google Scholar
• CARDAKLI F, SMYTHE B, EISELE J et al.: Effect of chronic apraclonidine treatment on intraocular pressure in advanced glaucoma. J. Glaucoma (1992) 1:271–278.
   PubMedGoogle Scholar
• LISH A, CAMRAS C, PODOS S: Effect of apraclonidine on intraocular pressure in glaucoma patients receiving maximally tolerated medication. J. Glaucoma (1992) 1:19–22.
   Google Scholar
• ROBIN AL: Questions concerning the role of apraclo-nidine in the management of glaucoma. Arch. Ophthal-mol. (1995) 113:712–714.
   PubMed Web of Science ®Google Scholar
• BULTER PJ, JONES B: Incidence of characteristics ofallergic reaction to apraclonidine 0.5%. Invest. Ophthal-mol Vis. Sci. (1996) 37(3):5201. Abstract #936.
   Google Scholar
• NAGASUBRAMANIAN S, HITCHINGS RA, DEMAILLY P et al: Comparison of apraclonidine and timolol in chronic open-angle glaucoma. A three-month study. Ophthal-mology (1993) 100:1318–1323.
   PubMed Web of Science ®Google Scholar
• ARAUJO SV, BOND JB, WILSON RP et at: Long-term effect of apraclonidine. Br. J. Ophthalmol. (1995) 79(12):1098–1101.
   PubMed Web of Science ®Google Scholar
• STEWART WC, LAIBOVITZ R, HORWITZ B et at: A 90-daystudy of the efficacy and side-effects of 0.25% and 0.5% apraclonidine vs. 0.5% timolol. Arch. Ophthalmol. (1996) 114:938–942.
   PubMedGoogle Scholar
• BUTLER P, MANNSCHRECK M, LIN S et al.: Clinical expe-rience with the long-term use of 1% apraclonidine: incidence of allergic reactions. Arch. Ophthalmol. (1995) 113:293–296.
   PubMed Web of Science ®Google Scholar
• MUNK SA, WIESE A, THOMPSON CD et al.: Oxidation potential and allergic response of a2-agonists. Invest. Ophthalmol. Vis. ScL (1996) 37:S832. Abstract #3839.
   Google Scholar
• SERDAHL CL, GALUSTIAN J, LEWIS RA: The effects of apraclonidine on conjunctival oxygen tension. Arch. Ophthalmol. (1989) 107:1777–1779.
   PubMed Web of Science ®Google Scholar
• CHANDLER ML, DESANTIS L: Studies of p-amino clo-nidine as a potential antiglaucom a age nt. Invest. Ophthal-mol Vis. ScL (1985) 26\(Suppl. 3):227. Abstract #93.
   Google Scholar
• FAHRENBACH WH, BACON DR, VAN BUSKIRK EM: Va-soactive drug effects on the uveal vasculature of the rabbit: a corrosion casting study. Invest. Ophthalmol Vis. Sri. (1989) 30 (Suppl.) :100. Abstract.
   Google Scholar
• BASU S, SJOQUIST B, STJERNSCHANTZ J et al.: Corneal permeability to and ocular metabolism of phenyl sub-stituted prostaglandin esters in vitro. Prostaglandins Leukotrienes and Essential Fat Oi Acids (1994) 50:161–168.
   PubMed Web of Science ®Google Scholar
• STJERNSCHANTZ J, SELÉN G, SJOQUIST Bet al.: Preclinical pharmacology of latanoprost, a phenyl-substituted PGF2a analogue. Advances in Prostaglandin, Thrombox-ane, and Leukotriene Research (1995) 23:513–518.
   Google Scholar
• GABELT BAT, KAUFMAN PL: Prostaglandin F2a in-creases uveoscleral outflow in the cynomolgus mon-key. Exp. Eye Res. (1989) 49:389–402.
   PubMed Web of Science ®Google Scholar
• CAMRAS CB, UNITED STATES LATANOPROST STUDY GROUP: Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. Oph-thalmology (1996) 103:138–147.
   PubMed Web of Science ®Google Scholar
• ALM A, STJERNSCHANTZ J, SCANDINAVIAN LATANO-PROST STUDY GROUP: Effects on intraocular pressure and side-effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Ophthalmology (1995) 102(12):1743–1752.
   Google Scholar
• WATSON P, STJERNSCHANTZ J, LATANOPROST STUDY GROUP: A six-month, randomized, double-masked study comparing latanoprost with timolol in open-an-gle glaucoma and ocular hypertension. Ophthalmology (1996) 103:126–127.
   PubMed Web of Science ®Google Scholar
• SAKURAI M, ARAIE M, OSHIKA T et al. Effects of topical application of UF-021, a novel prostaglandin derivative, on aqueous humor dynamics in normal human eyes. Jpn.J. Ophthalmol (1991) 35(2):156–165.
   PubMed Web of Science ®Google Scholar
• AZUMA I, MASUDA K, KITAZAWA Y et al: Double-maskedcomparative study of UF-021 and timolol ophthalmic solutions in patients with primary open-angle glau-coma or ocular hypertension. Jpn. J. Ophthalmol. (1993) 37:514–525.
   PubMed Web of Science ®Google Scholar
• HARIA M, SPENCER CM: Unoprostone (isopropyl uno-prostone). Drugs Aging (1996) 9 (3) :213-218. Discussion 219–220.
   Google Scholar
• CLINESCHMIDT CM, STRAHLMAN ER, ANDERSON K et al:Comparison of a fixed combination of dorzolamide and timolol (BID) to concomitant administration of dorzo-lamide (TID) plus timolol (BID) in patients with open-angle glaucoma for three months. Invest. Ophthalmol. Vis. ScL (1995) 36(4):5736. Abstract #3405.
   Google Scholar
• STROHMAIER K, SNYDER E, ADAMSONS I: Long-termsafety and efficacy of COSOPT, a fixed combination of dorzolamide and timolol. Invest. Ophthalmol Vis. Sci. (1996) 37(3):51102. Abstract #5069.
   Google Scholar
• VORVVERK CK, LIPTON SA, ZURAKOWSKI D et al: Chronic low-dose glutamate is toxic to retinal ganglion cells. Toxicity blocked by memantine. Invest. Ophthalmol Vis. ScL (1996) 37:1618–1624.
   PubMed Web of Science ®Google Scholar
• BURKE J, MANLAPAZ C, KHARLAMB A et al.: Therapeutic use of ay-adrenoceptor agonists in glaucoma. In: Alpha2-Adrenergic Receptors: Structure, Function and Therapeutic Implications. Lanier S, Limbird L (Eds.), Harwood Academic Publishers, Reading, UK (1996):179–187.
   Google Scholar
• TORIS CB, GLEASON ML, CAMRAS CB et al.: Effects of brimonidine on aqueous humor dynamics in human eyes. Arch. Ophthalmol (1995) 113:1514–1517.
   PubMed Web of Science ®Google Scholar
• ROBIN AL, NOVACK GD: a2-Agonists in the therapy of glaucoma. In: Pharmacology of Glaucoma. Drance SM, Van Buskirk EM, Neufeld AH (Eds.), Williams and Wilkins, Balti-more (1992):103–124.
   Google Scholar
• DERICK RJ: Adrenergic agonist medications: basic mechanisms. J. Glaucoma (1995) 4 (Suppl. 1):S1–S7.
   Google Scholar
• LEFKOWITZ RJ, HOFFMAN BB, TAYLOR P: Drugs acting at synaptic and neuroeffector junctional sites. In: Good-man and Gilman 's The Pharmacological Basis of Therapeu-tics (9th Edition). Hardman JG, Gilman AG, Limbird LE (Eds.), McGraw-Hill, New York (1996):105–139.
   Google Scholar
• ROBIN AL: Short-term effects of unilateral 1% apraclo-nidine therapy. Arch. Ophthalmol (1988) 106:912–915.
   PubMed Web of Science ®Google Scholar
• MUNK SA, GLUCHOWSKI C, DOLBY L et al.: Analogs of UK-14,304 as alphaz-adrenoceptor agonists. Twist and agent polarity as design elements. Bioorg. Med. Chem. Lett. (1994) 4:459–462.
   Web of Science ®Google Scholar
• MUNK SA, HARCOURT D, ARASASINGHAM Petal.: Analogs of UK 14,304: structural features responsible for az adrenoceptor activity. Bioorg Med. Chem. Lett. (1995) 5 (15) :1745–1750.
   Google Scholar
• BURKE J, SCHWARTZ M: Preclinical evaluation of bri-monidine. Surv. Ophthalmol. (1996) 41 (Suppl.):S9–518.
   Google Scholar
• MANLAPAZ CA, KHARLAMB AB, WILLIAMS LS et al.: IOP, pulmonary and cardiac effects of anti-glaucoma drugs brimonidine (ALPHAGAIsr), timolol and betaxolol. In-vest. Ophthalmol Vis. ScL (1997) 38(Suppl.):5814. Abstract 3792.
   Google Scholar
• BURKE IA, POTTER DE: Ocular effects of a relatively selective az agonist (UK-14, 304-18) in cats, rabbits and monkeys. Curr. Eye Res. (1986) 5:655–676.
   PubMedGoogle Scholar
• SERLE JB, STEIDL S, WANG RF et al.: Selective ay-adrener-gic agonists B-HT 920 and UK 14,304-18: effects on aqueous humor dynamics in monkeys. Arch. Ophthal-mol (1991) 109:1158–1162.
   PubMed Web of Science ®Google Scholar
• GABELT BT, ROBINSON JC, HUBBARD WC et al: Apraclo-nidine and brimonidine effects on anterior ocular and cardiovascular physiology in normal and sympathec-tomized monkeys. ap. Eye Res. (1994) 59(6):633–644.
   PubMed Web of Science ®Google Scholar
• BURKE J, KHARLAMB A, SHAN T et al.: Adrenergic and imidazoline receptor-mediated responses to UK-14,304-18 (brimonidine) in rabbits and monkeys: a species difference. In: The Imidazoline Receptor: Pharmacology, Functions, Ligands,, and Relevance to Biology and Medicine. Reis D, Bousquet P, Parini A (Eds.), The New York Academy of Sciences, New York (1995):78–95.
   Google Scholar
• ACHEAMPONG AA, SHACKLETON M, TANG-LIU DD-S: Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1997) 6(8) pigmented rabbits. Drug Metab. Dispos. (1995) 23 (7) 708–712.
   Google Scholar
• CHIEN D-S, RICHMAN J, ZOLEZIO H: Drug distribution of brimonidine in albino and pigmented rabbit eyes. Phar-maceut. Res. (1992) 9(Suppl.):S-336. Abstract #PPDM 8320.
   Google Scholar
• SPADA CS, NIEVES AL, BURKE JA et al.: Comparative effects of a2-adrenoceptor agonists on microvessel cali-ber in human retinal tissue. In: Sixth World Congress for 11/licrocirculation. Messmer K, Kubler W, (Eds.), (1996) 511–514.
   Google Scholar
• JOYNER WL, GILMORE JP: Tissues grafted into the ham-ster cheek pouch. In: Physical Techniques in Biology and Medicine (VolumeX). Baker CH, NastokWL (Eds.), Academic Press, New York (1986) Chapter 1:3–17.
   Google Scholar
• SPADA CS, NIEVES AL, BURKE JA et al.: Comparative effects of brimonidine, p-aminoclonidine and do-nidine on arteriolar caliber in human retinal tissue. Invest. Ophthalmol Vis. Sci. (1995) 36:S1041. Abstract 4817.
   Google Scholar
• BHANDARI A, ORGUL S, BACON D et al.: Effect of bri-monidine on optic nerve blood flow in rabbits. Invest. Ophthalmol Vis. Sci. (1997) 38(Suppl.):S783. Abstract 3631.
   Google Scholar
• LACHKAR Y, MIGDAL C, DHANJIL S et al.: The effect of brimonidine on ocular blood flow. Invest. Ophthalmol. Vis. Sci. (1997) 38(Suppl.):S778. Abstract 3602.
   Google Scholar
• MATER C, STEINBERG GK, SUN GH etal: Neuroprotection by the alpha-2 adrenoreceptor agonist dexmedetomid-ine in a focal model of cerebral ischemia. Anesthesiology (1993) 79:306–312.
   PubMed Web of Science ®Google Scholar
• REIS DJ, REGUNATHAN S, MEELEY MP: Imidazole recep-tors and clonidine-displacing substance in relationship to control of blood pressure, neuroprotection, and adrenomedullary secretion. Am. J. Hypertens. (1992) 5:51S–57S.
   Google Scholar
• WEN R, CHENG T, LI Y et al.: Induction of bFGF gene expression in vivo in rat photoreceptors by the a2-ad-renergic agonists xylazine and clonidine. Soc. Neurosci. Abstr. (1995) 21 (Part 2, Suppl.):1045. Abstract.
   Google Scholar
• WEN R, CHENG T, LI Y et al.: Systemic application of a2-adrenergic agonists xylazine or clonidine induces bFGF expression in photoreceptors. Invest. Ophthalmol Vis. Sci. (1996) 37 (Suppl.):S436. Abstract #2003.
   Google Scholar
• IAI RK, HASSON D, WHEELER LA: Neuroprotective effect of ocular hypotensive a2-adrenoceptor agonist bri-monidine. Vision Res. (1996) 36(Suppl.):S154. Abstract #033.
   Google Scholar
• LYNCH DR, DAWSON TM: Secondary mechanisms in neuronal trauma. Curr. Opin. Neurol (1994) 7:175–186.
   Web of Science ®Google Scholar
• YOLES E, MULER S, SCHWARTZ M et al.: Injury-induced secondary degeneration of rat optic nerve can be at-tenuated by a2-adrenoceptor agonists AGN 191103 and brimonidine. Invest. Ophthalmol. Vis. Sci. (1996) 37\(Suppl. 3) :S114. Abstract #540.
   Google Scholar
• SCHUMAN JS: Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hyper-tension. Sun'. Ophthalmol. (1996) 41 (Suppl.):S27–S37.
   Google Scholar
• SERLE JB FOR THE BRIMONIDINE STUDY GROUP: A comparison of the safety and efficacy of twice-daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. Sun'. Ophthalmol (1996) 41 (Suppl.): S39–S47.
   Google Scholar
• THOMPSON CD, MACDONALD TL, GARST ME et al.: Mechanisms of adrenergic agonist induced allergy: bioactivation and antigen formation. Exp. Eye Res. (1997). In press.
   Google Scholar
• GORDON RN, RITCH R, LIEBMANN JM et al: Alpha agonist allergy: is there cross reactivity between apraclonidine and brimonidine? Invest. Ophthalmol. Vis. Sci. (1997) 38(Suppl.):S559. Abstract 2601.
   Google Scholar
• BILL A: Conventional and uveoscleral drainage of aque-ous humour in the cynomolgus monkeys (Maraca irus) at normal and high intraocular pressures. Exp. Eye Res. (1966) 5:45–54.
   PubMed Web of Science ®Google Scholar
• TORTS CB, CAMRAS CB, YABLONSKI ME etal.: Acute versus chronic effects of brimonidine on aqueous humor dynamics in human eyes. Invest. Ophthalmol. Vis. Sci. (1997) 38(Suppl.):5243. Abstract 1129.
   Google Scholar
• CHIEN D-S, HOMSY JJ, GLUCHOWSKI C et al.: Corneal and conjunctival/scleral penetration of p-aminoclonidine, AGN 190342, and clonidine in rabbit eyes. Curr. Eye Res. (1990) 9(10:1051–1059.
   PubMedGoogle Scholar
• ANGELOV 0, WIESE A, TANG-LIU D et al.: One year oral and one year ocular toxicity studies of AGN-190342-LF (brimonidine tartrate) in cynomolgus monkeys. Toxi-cologist (1994) 14(0:255. Abstract #975.
   Google Scholar
• ANGELOV 0, WIESE A, TANG-LIU D et al.: Preclinical safety profile of brimonidine. Eur. J. Ophthalmol. (1995) 5(2A Suppl.):156. Abstract #14.48.
   Google Scholar
• WALTERS TR: Development and use of brimonidine in treating acute and chronic IOP elevations: a review of safety, efficacy, dose response, and dosing studies. Surv. Ophthalmol (1996) 41 (Suppl.):S19–S26.
   Google Scholar
• NORDLUND JR, PASQUALE LR, ROBIN AL et al.: The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine. Arch. Ophthalmol (1995) 113:77–83.
   Google Scholar
• DERICK RJ, ROBIN AL, WALTERS TR et al.: Brimonidinetartrate: a one month dose response study. Ophthalmol-ogy (1997) 104:131–136.
   PubMed Web of Science ®Google Scholar